FOXM1 and acute lymphoblastic leukemia: In addition, we confirmed that inhibition of FOXM1 by the ARF26–44 peptide sensitized patient-derived Ph+ ALL cells towards TKI treatment compared with TKI treatment alone (Fig. 6f) and increased intracellular levels of ROS (Fig. 6g).